[go: up one dir, main page]

WO2002012499A3 - Haplotypes du gene ntf3 - Google Patents

Haplotypes du gene ntf3 Download PDF

Info

Publication number
WO2002012499A3
WO2002012499A3 PCT/US2001/024665 US0124665W WO0212499A3 WO 2002012499 A3 WO2002012499 A3 WO 2002012499A3 US 0124665 W US0124665 W US 0124665W WO 0212499 A3 WO0212499 A3 WO 0212499A3
Authority
WO
WIPO (PCT)
Prior art keywords
haplotypes
ntf3
gene
disclosed
ntf3 gene
Prior art date
Application number
PCT/US2001/024665
Other languages
English (en)
Other versions
WO2002012499A2 (fr
Inventor
Stefanie E Kliem
Beena Koshy
Elizabeth M Lanz
Original Assignee
Genaissance Pharmaceuticals
Stefanie E Kliem
Beena Koshy
Elizabeth M Lanz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaissance Pharmaceuticals, Stefanie E Kliem, Beena Koshy, Elizabeth M Lanz filed Critical Genaissance Pharmaceuticals
Priority to AU2001294513A priority Critical patent/AU2001294513A1/en
Publication of WO2002012499A2 publication Critical patent/WO2002012499A2/fr
Publication of WO2002012499A3 publication Critical patent/WO2002012499A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des nouveaux allèles génétiques du gène de la neurotrophine 3 (NTF3), ainsi que divers génotypes, haplotypes et paires d'haplotypes du gène NTF3, existant dans la population des Etats-Unis d'Amérique. L'invention concerne encore des compositions et procédés d'haplotypage et/ou de génotypage du gène NTF3, chez un individu. Enfin, l'invention concerne des polynucléotides définis par les haplotypes décrits dans le corps du brevet.
PCT/US2001/024665 2000-08-04 2001-08-06 Haplotypes du gene ntf3 WO2002012499A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001294513A AU2001294513A1 (en) 2000-08-04 2001-08-06 Haplotypes of the ntf3 gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22320800P 2000-08-04 2000-08-04
US60/223,208 2000-08-04

Publications (2)

Publication Number Publication Date
WO2002012499A2 WO2002012499A2 (fr) 2002-02-14
WO2002012499A3 true WO2002012499A3 (fr) 2003-08-28

Family

ID=22835526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024665 WO2002012499A2 (fr) 2000-08-04 2001-08-06 Haplotypes du gene ntf3

Country Status (2)

Country Link
AU (1) AU2001294513A1 (fr)
WO (1) WO2002012499A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103374628B (zh) * 2012-04-27 2016-08-17 中国科学院上海生命科学研究院 先天性心脏病相关基因fam71a及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005783A1 (fr) * 1991-09-20 1993-04-01 The General Hospital Corporation Procedes de diagnostic et de traitement de la maladie de parkinson
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
WO2000058519A2 (fr) * 1999-03-31 2000-10-05 Whitehead Institute For Biomedical Research Caracterisation de polymorphismes d'un seul nucleotide, dans des regions de codage de genes humains
WO2001080156A1 (fr) * 2000-04-18 2001-10-25 Genaissance Pharmaceuticals, Inc. Procede et systeme de determination d'haplotypes a partir d'une recueil de polymorphismes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005783A1 (fr) * 1991-09-20 1993-04-01 The General Hospital Corporation Procedes de diagnostic et de traitement de la maladie de parkinson
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
WO2000058519A2 (fr) * 1999-03-31 2000-10-05 Whitehead Institute For Biomedical Research Caracterisation de polymorphismes d'un seul nucleotide, dans des regions de codage de genes humains
WO2001080156A1 (fr) * 2000-04-18 2001-10-25 Genaissance Pharmaceuticals, Inc. Procede et systeme de determination d'haplotypes a partir d'une recueil de polymorphismes

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CARGILL M ET AL: "Characterization of single-nucleotide polymorphisms in coding regions of human genes", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 22, July 1999 (1999-07-01), pages 231 - 238, XP002121300, ISSN: 1061-4036 *
CLAIBORNE STEPHENS J: "SINGLE-NUCLEOTIDE POLYMORPHISMS, HAPLOTYPES AND THEIR RELEVANCE TO PHARMACOGENTICS", MOLECULAR DIAGNOSIS, NAPERVILLE, IL, US, vol. 4, no. 4, 1999, pages 309 - 317, XP002937520, ISSN: 1084-8592 *
CLARK A G ET AL: "HAPLOTYPE STRUCTURE AND POPULATION GENETIC INFERENCES FROM NUCLEOTIDE- SEQUENCE VARIATION IN HUMAN LIPOPROTEIN LIPASE", AMERICAN JOURNAL OF HUMAN GENETICS, UNIVERSITY OF CHICAGO PRESS, CHICAGO,, US, vol. 63, 1998, pages 595 - 612, XP002937239, ISSN: 0002-9297 *
DRYSDALE C M ET AL: "COMPLEX PROMOTER AND CODING REGION BETA2-ADRENERGIC RECEPTOR HAPLOTYPES ALTER RECEPTOR EXPRESSION AND PREDICT IN VIVO RESPONSIVENESS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 19, 12 September 2000 (2000-09-12), pages 10483 - 10488, XP002940094, ISSN: 0027-8424 *
EMILIEN G ET AL: "IMPACT OF GENOMICS ON DRUG DISCOVERY AND CLINICAL MEDICINE", QUARTERLY JOURNAL OF MEDICINE, CLARENDON PRESS, OXFORD, GB, vol. 93, no. 7, June 2000 (2000-06-01), pages 391 - 423, XP000941207, ISSN: 0033-5622 *
HATTORI M ET AL: "Association of neurotrophin-3 gene variant with severe forms of schizophrenia.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 17 APR 1995, vol. 209, no. 2, 17 April 1995 (1995-04-17), pages 513 - 518, XP001055072, ISSN: 0006-291X *
JONES K R ET AL: "Molecular cloning of a human gene that is a member of the nerve growth factor family.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES OCT 1990, vol. 87, no. 20, October 1990 (1990-10-01), pages 8060 - 8064, XP000159841, ISSN: 0027-8424 *
JUDSON R ET AL: "THE PREDICTIVE POWER OF HAPLOTYPES IN CLINICAL RESPONSE", PHARMACOGENOMICS, ASHLEY PUBLICATIONS, GB, vol. 1, no. 1, February 2000 (2000-02-01), pages 15 - 26, XP001113104, ISSN: 1462-2416 *
LU ANTONY Y H: "Drug-metabolism research challenges in the new millennium: Individual variability in drug therapy and drug safety.", DRUG METABOLISM AND DISPOSITION, vol. 26, no. 12, December 1998 (1998-12-01), pages 1217 - 1222, XP002223866, ISSN: 0090-9556 *
MAREZ D ET AL: "Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution", PHARMACOGENETICS, CHAPMAN & HALL, LONDON, GB, vol. 7, no. 3, 1997, pages 193 - 202, XP002955538, ISSN: 0960-314X *
ROSENTHAL A ET AL: "PRIMARY STRUCTURE AND BIOLOGICAL ACTIVITY OF A NOVEL HUMAN NEUROTROPHIC FACTOR", NEURON, CAMBRIDGE, MA, US, vol. 4, 1 May 1990 (1990-05-01), pages 767 - 773, XP000386322 *
RUANO G ET AL: "GENOTYPING AND HAPLOTYPING OF POLYMORPHISMS DIRECTLY FROM GENOMIC DNA VIA COUPLED AMPLIFICATION AND SEQUENCING (CAS)", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 19, no. 24, 1991, pages 6877 - 6882, XP000197814, ISSN: 0305-1048 *
RUANO: "Genaissance awarded broad patent on methods for collecting genes for variation analysis across populations", GENAISSANCE PRESS RELEASE, 8 November 1999 (1999-11-08), XP002229209, Retrieved from the Internet <URL:www.biomedicine.ch/publications/genaissance/g111199.html> [retrieved on 20030129] *
ULBRECHT M ET AL: "Assoziation of beta 2-adrenoreceptor variants with bronchial hyperresponsiveness", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 161, no. 2, February 2000 (2000-02-01), pages 469 - 474, XP002188594, ISSN: 1073-449X *

Also Published As

Publication number Publication date
WO2002012499A2 (fr) 2002-02-14
AU2001294513A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
WO2002006294A3 (fr) Haplotypes du gene mmp13
WO2001079234A3 (fr) Haplotypes du gene apoe
WO2002018414A3 (fr) Haplotypes du gène bf
WO2002010454A3 (fr) Haplotypes du gene alas2? ¿
WO2002012499A3 (fr) Haplotypes du gene ntf3
WO2002090512A3 (fr) Haplotypes du gene nnmt
WO2002040502A3 (fr) Haplotypes du gene de la lipase hormono-sensible
WO2002012562A3 (fr) Haplotypes du gene pla2g1b
WO2002090378A3 (fr) Haplotypes du gene de ces2
WO2001087909A3 (fr) Haplotypes du gene aanat
WO2001090127A3 (fr) Haplotypes du gene de hoxd3
WO2002050098A3 (fr) Haplotypes du gene du recepteur de la prolactine (prlr)
WO2001090126A3 (fr) Haplotypes du gene snap29
WO2001092278A3 (fr) Haplotypes du gene rlbp1
WO2002030950A3 (fr) Haplotypes du gene fy
WO2001090118A3 (fr) Haplotypes du gene edn2
WO2002016399A3 (fr) Haplotypes du gene tacr1
WO2001094362A3 (fr) Haplotypes du gene acp2
WO2002032924A3 (fr) Haplotypes du gene chrm5
WO2002042320A3 (fr) Haplotypes du gene de glutathione reductase
WO2002055534A3 (fr) Haplotypes du gene f2rli
WO2002094850A3 (fr) Haplotypes du gene gnrh2
WO2002002580A3 (fr) Haplotypes du gene etfb
WO2001087907A3 (fr) Haplotypes du gene de l&#39;osm
WO2002038586A3 (fr) Haplotypes du gene il6

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref country code: WO

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP